Li et al. analyzed 1104 BC samples, of which 38.7% were luminal A, 17.1% luminal B, 6.1% HER2+, 12.8 triple-negative, and the remaining sample subtypes were not applicable. This evidence concerns the gene ERBB2 and breast cancer.